These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 25741640)
1. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain. Riebenfeld D; Spirk D; Mathis A; Villiger L; Gerber PA; Gasser UE; Lehmann R Swiss Med Wkly; 2015; 145():w14114. PubMed ID: 25741640 [TBL] [Abstract][Full Text] [Related]
2. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study]. Spirk D; Lareida J; Scheidegger K; Diem P Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638 [TBL] [Abstract][Full Text] [Related]
3. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS). Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198 [No Abstract] [Full Text] [Related]
5. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616 [TBL] [Abstract][Full Text] [Related]
6. Effect of Telephone-Delivered Interventions on Glycemic Control in Type 2 Diabetes Treated with Glargine Insulin. Bellido V; Bellido D; Tejera C; Carral F; Goicolea I; Soto A; García Almeida JM; Morales C; López de la Torre M Telemed J E Health; 2019 Jun; 25(6):471-476. PubMed ID: 30036160 [No Abstract] [Full Text] [Related]
7. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD; Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260 [TBL] [Abstract][Full Text] [Related]
8. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Halberg IB; Lyby K; Wassermann K; Heise T; Zijlstra E; Plum-Mörschel L Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095 [TBL] [Abstract][Full Text] [Related]
10. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB; JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259 [TBL] [Abstract][Full Text] [Related]
11. Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. Owens DR; Landgraf W; Frier BM; Zhang M; Home PD; Meneghini L; Bolli GB Diabetes Obes Metab; 2019 Feb; 21(2):321-329. PubMed ID: 30520217 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Yu M; Brunt KV; Milicevic Z; Varnado O; Boye KS Clin Ther; 2017 Nov; 39(11):2284-2295. PubMed ID: 29110972 [TBL] [Abstract][Full Text] [Related]
13. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study. Li X; Du T; Li W; Zhang T; Liu H; Xiong Y Clin Ther; 2014 Sep; 36(9):1269-75. PubMed ID: 25062651 [TBL] [Abstract][Full Text] [Related]
15. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Owens DR; Traylor L; Mullins P; Landgraf W Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788 [TBL] [Abstract][Full Text] [Related]
16. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Davies MJ; Russell-Jones D; Barber TM; Lavalle-González FJ; Galstyan GR; Zhu D; Baxter M; Dessapt-Baradez C; McCrimmon RJ Diabetes Obes Metab; 2019 Aug; 21(8):1967-1972. PubMed ID: 31124299 [TBL] [Abstract][Full Text] [Related]
17. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Guo W; Tian W; Lin L; Xu X Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Seufert J; Pegelow K; Bramlage P Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985 [TBL] [Abstract][Full Text] [Related]
19. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes. Pohlmeier H; Berard L; Brulle-Wohlhueter C; Wu J; Dahmen R; Nowotny I; Klonoff D J Diabetes Sci Technol; 2017 Mar; 11(2):263-269. PubMed ID: 27664062 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]